|Description:||1. Lanatoside C, a cardiac glycoside, is an anti-arrhythmic agent. |
2. Lanatoside C acts through protein kinase Cδ to cause apoptosis of human hepatocellular carcinoma cells.
3. Lanatoside C can effectively inhibit all four serotypes of dengue virus, flavivirus Kunjin, alphavirus Chikungunya and Sindbis virus as well as the human enterovirus 71, suggest that lanatoside C possesses broad spectrum antiviral activity against several groups of positive-sense RNA viruses.
|Targets:||Akt | mTOR | PKC | Antifection|
|Source:||The herbs of Digitalis lanata|
|Solvent:||DMSO, Pyridine, Methanol, Ethanol, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: firstname.lastname@example.org
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||1.0151 mL||5.0756 mL||10.1513 mL||20.3025 mL||25.3781 mL|
|5 mM||0.203 mL||1.0151 mL||2.0303 mL||4.0605 mL||5.0756 mL|
|10 mM||0.1015 mL||0.5076 mL||1.0151 mL||2.0303 mL||2.5378 mL|
|50 mM||0.0203 mL||0.1015 mL||0.203 mL||0.4061 mL||0.5076 mL|
|100 mM||0.0102 mL||0.0508 mL||0.1015 mL||0.203 mL||0.2538 mL|
Sci Rep. 2017 Apr 7;7:46134.
|Lanatoside C, a cardiac glycoside, acts through protein kinase Cδ to cause apoptosis of human hepatocellular carcinoma cells.[Pubmed: 28387249 ]|
|Recent studies have revealed that cardiac glycosides, such as digitalis and digoxin, have anticancer activity and may serve as lead compounds for the development of cancer treatments. The poor prognosis of hepatocellular carcinoma (HCC) patients reflects the development of resistance to current chemotherapeutic agents, highlighting the need for discovering new small-molecule therapeutics. Here, we found that Lanatoside C, an anti-arrhythmic agent extracted from Digitalis lanata, inhibited the growth of HCC cells and dramatically decreased tumor volume as well as delayed tumor growth without obvious body weight loss.We also found that the AKT/mTOR pathway was negatively regulated by Lanatoside C through PKCδ activation. In conclusion, we provide the first demonstration that the anticancer effects of Lanatoside C are mainly attributable to PKCδ activation.|
Antiviral Res. 2014 Nov;111:93-9
|Antiviral activity of lanatoside C against dengue virus infection.[Pubmed: 25251726 ]|
|Our data revealed that Lanatoside C has an IC50 of 0.19μM for dengue virus infection in HuH-7 cells. Dose-dependent reduction in dengue viral RNA and viral proteins synthesis were also observed upon treatment with increasing concentrations of Lanatoside C. Time of addition study indicated that Lanatoside C inhibits the early processes of the dengue virus replication cycle. Furthermore, Lanatoside C can effectively inhibit all four serotypes of dengue virus, flavivirus Kunjin, alphavirus Chikungunya and Sindbis virus as well as the human enterovirus 71. These findings suggest that Lanatoside C possesses broad spectrum antiviral activity against several groups of positive-sense RNA viruses.|
Neuro Oncol. 2011 Nov;13(11):1213-24.
|Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway.[Pubmed: 21757445 ]|
|Human glioblastoma (GBM) cells are notorious for their resistance to apoptosis-inducing therapeutics. We have identified Lanatoside C as a sensitizer of GBM cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell death partly by upregulation of the death receptor 5. We show that Lanatoside C sensitizes GBM cells to TRAIL-induced apoptosis in a GBM xenograft model in vivo. Lanatoside C on its own serves as a therapeutic agent against GBM by activating a caspase-independent cell death pathway. Cells treated with Lanatoside C showed necrotic cell morphology with absence of caspase activation, low mitochondrial membrane potential, and early intracellular ATP depletion. In conclusion, Lanatoside C sensitizes GBM cells to TRAIL-induced cell death and mitigates apoptosis resistance of glioblastoma cells by inducing an alternative cell death pathway. To our knowledge, this is one of the first examples of use of caspase-independent cell death inducers to trigger tumor regression in vivo. Activation of such mechanism may be a useful strategy to counter resistance of cancer cells to apoptosis.|